vs
Apellis Pharmaceuticals, Inc.（APLS）与FLEXSTEEL INDUSTRIES INC（FLXS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是FLEXSTEEL INDUSTRIES INC的1.7倍（$199.9M vs $115.1M），FLEXSTEEL INDUSTRIES INC净利率更高（17.7% vs -29.5%，领先47.2%），FLEXSTEEL INDUSTRIES INC同比增速更快（1.0% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 1.9%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Flexsteel Industries Inc是一家总部位于美国的家具制造商，设计、生产并销售各类软垫住宅家具、商用家具及酒店家具，主要面向北美市场运营，通过广泛的分销网络服务终端消费者、零售合作伙伴及企业客户。
APLS vs FLXS — 直观对比
营收规模更大
APLS
是对方的1.7倍
$115.1M
营收增速更快
FLXS
高出6.9%
-5.9%
净利率更高
FLXS
高出47.2%
-29.5%
两年增速更快
APLS
近两年复合增速
1.9%
损益表 — Q4 FY2025 vs Q1 FY2027
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $115.1M |
| 净利润 | $-59.0M | $20.4M |
| 毛利率 | — | 22.6% |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 17.7% |
| 营收同比 | -5.9% | 1.0% |
| 净利润同比 | -62.2% | 116.0% |
| 每股收益（稀释后） | $-0.40 | $1.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSFLXS
| Q3 26 | — | $115.1M | ||
| Q4 25 | $199.9M | $118.2M | ||
| Q3 25 | $458.6M | $110.4M | ||
| Q2 25 | $178.5M | $114.6M | ||
| Q1 25 | $166.8M | $114.0M | ||
| Q4 24 | $212.5M | $108.5M | ||
| Q3 24 | $196.8M | $104.0M | ||
| Q2 24 | $199.7M | $110.8M |
净利润APLSFLXS
| Q3 26 | — | $20.4M | ||
| Q4 25 | $-59.0M | $6.6M | ||
| Q3 25 | $215.7M | $7.3M | ||
| Q2 25 | $-42.2M | $10.7M | ||
| Q1 25 | $-92.2M | $-3.7M | ||
| Q4 24 | $-36.4M | $9.1M | ||
| Q3 24 | $-57.4M | $4.1M | ||
| Q2 24 | $-37.7M | $4.9M |
毛利率APLSFLXS
| Q3 26 | — | 22.6% | ||
| Q4 25 | — | 22.7% | ||
| Q3 25 | — | 23.5% | ||
| Q2 25 | — | 23.9% | ||
| Q1 25 | — | 22.2% | ||
| Q4 24 | — | 21.0% | ||
| Q3 24 | — | 21.5% | ||
| Q2 24 | — | 21.3% |
营业利润率APLSFLXS
| Q3 26 | — | — | ||
| Q4 25 | -25.6% | 7.6% | ||
| Q3 25 | 48.7% | 8.1% | ||
| Q2 25 | -18.6% | 12.2% | ||
| Q1 25 | -50.0% | -4.4% | ||
| Q4 24 | -12.3% | 10.7% | ||
| Q3 24 | -24.0% | 5.8% | ||
| Q2 24 | -14.7% | 6.9% |
净利率APLSFLXS
| Q3 26 | — | 17.7% | ||
| Q4 25 | -29.5% | 5.6% | ||
| Q3 25 | 47.0% | 6.6% | ||
| Q2 25 | -23.6% | 9.3% | ||
| Q1 25 | -55.3% | -3.3% | ||
| Q4 24 | -17.1% | 8.3% | ||
| Q3 24 | -29.2% | 4.0% | ||
| Q2 24 | -18.9% | 4.4% |
每股收益（稀释后）APLSFLXS
| Q3 26 | — | $1.14 | ||
| Q4 25 | $-0.40 | $1.18 | ||
| Q3 25 | $1.67 | $1.31 | ||
| Q2 25 | $-0.33 | $1.90 | ||
| Q1 25 | $-0.74 | $-0.71 | ||
| Q4 24 | $-0.30 | $1.62 | ||
| Q3 24 | $-0.46 | $0.74 | ||
| Q2 24 | $-0.30 | $0.87 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $57.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $185.3M |
| 总资产 | $1.1B | $290.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSFLXS
| Q3 26 | — | $57.3M | ||
| Q4 25 | $466.2M | $36.8M | ||
| Q3 25 | $479.2M | $38.6M | ||
| Q2 25 | $370.0M | $40.0M | ||
| Q1 25 | $358.4M | $22.6M | ||
| Q4 24 | $411.3M | $11.8M | ||
| Q3 24 | $396.9M | $5.7M | ||
| Q2 24 | $360.1M | $4.8M |
股东权益APLSFLXS
| Q3 26 | — | $185.3M | ||
| Q4 25 | $370.1M | $178.9M | ||
| Q3 25 | $401.2M | $172.2M | ||
| Q2 25 | $156.3M | $167.9M | ||
| Q1 25 | $164.2M | $158.1M | ||
| Q4 24 | $228.5M | $161.9M | ||
| Q3 24 | $237.1M | $154.7M | ||
| Q2 24 | $264.3M | $150.4M |
总资产APLSFLXS
| Q3 26 | — | $290.2M | ||
| Q4 25 | $1.1B | $290.2M | ||
| Q3 25 | $1.1B | $281.5M | ||
| Q2 25 | $821.4M | $282.5M | ||
| Q1 25 | $807.3M | $266.1M | ||
| Q4 24 | $885.1M | $271.5M | ||
| Q3 24 | $901.9M | $268.7M | ||
| Q2 24 | $904.5M | $274.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $27.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 1.33× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSFLXS
| Q3 26 | — | $27.2M | ||
| Q4 25 | $-14.2M | $1.0M | ||
| Q3 25 | $108.5M | $4.1M | ||
| Q2 25 | $4.4M | $15.6M | ||
| Q1 25 | $-53.4M | $12.3M | ||
| Q4 24 | $19.4M | $6.7M | ||
| Q3 24 | $34.1M | $2.4M | ||
| Q2 24 | $-8.3M | $7.5M |
自由现金流APLSFLXS
| Q3 26 | — | — | ||
| Q4 25 | $-14.3M | $-735.0K | ||
| Q3 25 | $108.3M | $2.8M | ||
| Q2 25 | $4.4M | $15.1M | ||
| Q1 25 | $-53.4M | $10.9M | ||
| Q4 24 | $19.3M | $5.8M | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | $-8.4M | $7.1M |
自由现金流率APLSFLXS
| Q3 26 | — | — | ||
| Q4 25 | -7.1% | -0.6% | ||
| Q3 25 | 23.6% | 2.5% | ||
| Q2 25 | 2.5% | 13.1% | ||
| Q1 25 | -32.0% | 9.6% | ||
| Q4 24 | 9.1% | 5.3% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | -4.2% | 6.4% |
资本支出强度APLSFLXS
| Q3 26 | — | — | ||
| Q4 25 | 0.1% | 1.5% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 0.8% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | 0.0% | 0.4% |
现金转化率APLSFLXS
| Q3 26 | — | 1.33× | ||
| Q4 25 | — | 0.15× | ||
| Q3 25 | 0.50× | 0.56× | ||
| Q2 25 | — | 1.46× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.58× | ||
| Q2 24 | — | 1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
FLXS
暂无分部数据
